-
Mashup Score: 10Rollback of Prescription Delivery Flexibilities Poses Challenges for At-Risk Cancer Patients - 6 month(s) ago
Research presented at the 2023 ASCO Quality Care Symposium revealed unequal impacts on patients from recent policy changes preventing home delivery of prescription oncology medication.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Opinion | In a Golden Age of Cancer Care, PBMs Are Holding Us Back - 9 month(s) ago
We must stop predatory and destructive behaviors
Source: www.medpagetoday.comCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/EIQoNsxNAE @TheUSONetwork @TexasOncology @oncologyCOA @OSSatACCC @ASCO
-
-
Mashup Score: 1Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology - 9 month(s) ago
Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, “Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care.”
Source: www.ajmc.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @oncologyCOA: Oncology Onward: A Conversation With @dapattmd of Texas Oncology - from @AJMC_Journal https://t.co/C3jBQ4HmGY
-
-
Mashup Score: 0
Few treatment options are available for patients with advanced renal cell carcinoma who have received previous anti-PD-1-based or anti-PD-L1-based imm…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study - ScienceDirect @DrChoueiri @ASCO @DanaFarberNews https://t.co/r3qw2pyO5C
-
-
Mashup Score: 3Healio Disruptive Innovators Awards 2023 - 1 year(s) ago
Vote for your 2023 Healio Disruptive Innovators!
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @HemOncToday: 1 week to help @WIMSummit, @ShikhaJainMD, @GoHealio by voting for Woman Disruptor of the Year: https://t.co/Go8fI6UQE2 @N…
-
-
Mashup Score: 1
Most new cancer drugs require biomarker testing to match medication to protein, genetics of that tumor.
Source: Austin American-StatesmanCategories: Latest Headlines, Oncologists1Tweet-
RT @VivekSubbiah: Texas lawmakers push for insurers to cover biomarker testing for cancer @dapattmd https://t.co/uifooAqvTF via @statesman
-
-
Mashup Score: 0
Most new cancer drugs require biomarker testing to match medication to protein, genetics of that tumor.
Source: Austin American-StatesmanCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to see Policy in Texas supporting cancer care @ACSCAN @ASCO @oncologyCOA @TexasOncology @texmed https://t.co/1U7EMeeiuj
-
-
Mashup Score: 0The Fight for Affordable Safe Breast Reconstruction - 1 year(s) ago
Local surgeon Dr. Elizabeth Potter leads the fight to protect safe breast reconstruction surgeries under insurance.
Source: Austin Woman MagazineCategories: Hem/Oncs, Latest HeadlinesTweet-
The Fight for Affordable Safe Breast Reconstruction @asco @TheUSONetwork @oncologyCOA @texmed @TexasTribune https://t.co/62dReucldm
-
-
Mashup Score: 0Community Oncology Conference '23 | Transform. Adapt. Evolve. - 1 year(s) ago
Register today for the Community Oncology Conference! The COA Conference brings cutting edge info from renowned experts throughout community oncology. Register!
Source: Community Oncology ConferenceCategories: Hem/Oncs, Latest HeadlinesTweet-
As you serve your patients in 2023, make it easier to succeed by attending #COA2023 on March 23-24 in Kissimmee, Florida! #communityoncology https://t.co/UT55jZOmoh
-
-
Mashup Score: 0ASCO Election - 2 year(s) ago
ASCO Election
Source: ASCOCategories: Hem/Oncs, Latest HeadlinesTweet-
Today is the day to get out the vote in all the elections! @oncologyCOA @ASCO @ASCOPres @WeAreWLO https://t.co/jGVtMSVT6P https://t.co/tXILIzN0td
-
Rollback of Prescription Delivery Flexibilities Poses Challenges for At-Risk Cancer Patients @ASCO @oncologyCOA @nickcf @TedOkonCOA @TheUSONetwork @TexasOncology @CMSGov @LizFowler_ https://t.co/4PiLXTJKnF